Peter Ottsjö is a tech journalist and author of the popular science book Evigt Ung (Forever Young), CEO of LEVITY Media Group and co-host of the LEVITY Podcast, Longevity Biotech Fellowship fellow and Vitalist.
Aug 24, 2026
•
13 min read
Plus: Lady Gaga enters AI x bio, antibody AI gets a CASP-like reality check, and Arc raises the bar for virtual cells.
Aug 20, 2026
5 min read
Plus: What Claude actually did in Anthropic’s protein-design experiment
Aug 18, 2026
12 min read
AIDO Cell is GenBio’s first concrete step toward an AI-Driven Digital Organism - BAIO got an early look at the launch and spoke with co-founder Eric Xing.
Aug 17, 2026
8 min read
Plus: protein models get the LLM alignment treatment, AI learns protein motion from missing data, and Benchling puts wet-lab judgment to the test.
Aug 13, 2026
7 min read
A three-stage blueprint for connecting biological AI models to a digital organism.
Plus: Aureka raises $100M for a biological world model, and AI cuts years of trial-and-error from prime editing.
TOP 10
Aug 12, 2026
9 min read
A Phase III AI drug, a $3.8 billion protein-design startup, living-cell trajectories, and AI redesigning the gene-editing machine.
Aug 10, 2026
Plus: four Google legends launch Discovery Loop, autonomous labs get a blueprint, and Jura finds a scaling law for AI in biology.
Aug 3, 2026
10 min read
Plus: GSK backs cell models, AI reopens a cancer trial, and DeepMind breaks up the AlphaFold team.
Jul 30, 2026
Plus: AI hunts for cancer before diagnosis, and Atlas wants to predict who will respond before a clinical trial begins.
Jul 29, 2026
19 min read
Derya Unutmaz: “Fable 5 is a great model and they can just restrict it whatever the way they find is right”
Jul 27, 2026
Plus: why biology needs open weights, and AlphaFold3 helps gene editors make fewer mistakes.
Jul 23, 2026
Plus: PeptiVerse predicts whether peptides have drug-like properties, and BrainPilot brings AI agents to neuroscience.
Jul 20, 2026
Plus: Lila’s scientific-superintelligence claims, Google’s AI biosecurity stack, and a model that reads gene activity as an image.
Jul 16, 2026
Plus: Chai reaches a $3.8B valuation with Lilly, Pfizer and Novartis on board.
Jul 13, 2026
1 min read
Plus: Summer Mode switched on for BAIO.
Jul 9, 2026
Plus: Insilico’s AI-designed drug enters Phase III, Biohub finds psoriasis targets in skin cells, and ATHENA teaches medical AI to check its evidence.
Jul 6, 2026
6 min read
Plus: Valence models molecules in water, there's a new Virtual Cell challenge coming up, and Takeda adds Insilico to its AI drug-discovery ecosystem.
Jul 4, 2026
Claude Science, scientific superintelligence, ultrasound through the skull, and AI-designed antibodies for cancer’s hidden mutation flags.
Jul 1, 2026
We bring you all the news, how people reacted and the insights behind the launch.
Jun 29, 2026
Plus: AI reads more from ECGs, a garage drug candidate goes viral, and BAIO’s AI × bio tools directory is live.
Jun 25, 2026
Plus: Proto links biology’s AI silos, AI-CURA reads variant evidence, NVIDIA gives agents a toolbox, and GPT-5 Pro helps revisit a T-cell mystery.
Jun 22, 2026
Plus: OpenAI revisits rare-disease genomes, Benchling adds private lab context, and AlphaFold’s co-creator heads to Anthropic.
Jun 18, 2026
Plus: Tacit Labs builds long-horizon benchmarks for AI drug discovery, Radical Numerics adds a defense layer to genome AI, and Noetik predicts drug responders from pathology slides.
Jun 15, 2026
Plus: Claude Fable goes offline, Terray gives AI-designed molecules a recipe, TITO skips frames in molecular movies, and Tamarind powers Lilly’s TuneLab expansion
